Abstract
Introduction: The aim was to determine if one month taking BelAgeTM in the second trimester of pregnancy could reduce the risk of preeclampsia. Methods: From April 2019 to July 2020, a non-blinded, prospective, randomized, study was performed inviting women in the second trimester of pregnancy to take 3 g of BelAgeTM once daily for one month. The control group received only the nutritional assessment. Relative risk (RR) to develop preeclampsia with 95% confidence interval (CI) was calculated using the Social Science Statistics online software, considering a significant statistical value a P-value < 0.05. Results: 144 patients from the BelAgeTM group (mean age 23.6 ± 9.7), and 99 from the control group (mean age 22.1 ± 8.6) were included, finding differences basal systolic blood pressure (P = 0.03), final diastolic blood pressure (P = 0.002) and final mean blood pressure (P = 0.001). Preeclampsia was developed by 18 patients in the BelAgeTM group versus ten patients in the control group, RR 1.2 (95% CI, 0.60–2.57, P = 0.57). Conclusion: A short-time BelAgeTM prescription in the second trimester of pregnancy was enough to reduce the DBP, but did not reduce the risk of developing preeclampsia. Keywords: BelAgeTM diastolic blood pressure, preeclampsia, relative risk.
Highlights
The aim was to determine if one month taking BelAgeTM in the second trimester of pregnancy could reduce the risk of preeclampsia
It has been known lately that, in addition to the direct damage that free radicals can inflict on the molecules, imbalance in the redox state can alter the normal function of various signaling pathways that possess the physiological functions necessary to maintain the homeostasis of organisms.[11]
The recommended dose is to dilute 1 sachet a day in 16 ounce (≈ 500 ml) of water.[12]. This project aimed to determine the effects of a short period of BelAgeTM administration and nutritional management in patients who were in their second trimester of pregnancy and at a high risk of developing preeclampsia compared to those highrisk patients with only nutritional management
Summary
The aim was to determine if one month taking BelAgeTM in the second trimester of pregnancy could reduce the risk of preeclampsia. Preeclampsia complicates 3%–5% of pregnancies after 20 weeks of gestation in developed countries [1] but 16.7% of pregnancies in the developing world.[2] It is the leading cause of maternal death in developing of countries and a major contributor to maternal and perinatal morbidities. The recommended dose is to dilute 1 sachet a day in 16 ounce (≈ 500 ml) of water.[12] This project aimed to determine the effects of a short period of BelAgeTM administration and nutritional management in patients who were in their second trimester of pregnancy and at a high risk of developing preeclampsia compared to those highrisk patients with only nutritional management
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
